Eli Lilly (LLY) USD (CDI)
$22.68
(2.92%)
- Add to watchlist
- This stock can be held in a
$22.68
(2.92%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$22.68
(2.92%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
Eli Lilly's quarterly numbers disappoint, shares tumble
30 October 2024 11:25
(Sharecast News) - Shares in Eli Lilly & Co fell sharply on Wednesday, after the US drugs firm missed quarterly forecasts and cut its full-year outlook.
-
Eli Lilly hikes guidance as obesity drug sales soar
8 August 2024 14:11
(Sharecast News) - Eli Lilly significantly raised its full-year revenue forecast by $3bn on Thursday, after reporting a strong second quarter driven by the robust performance of its blockbuster weight loss...
-
Eli Lilly hikes guidance as obesity drug sales soar
8 August 2024 14:11
(Sharecast News) - Eli Lilly significantly raised its full-year revenue forecast by $3bn on Thursday, after reporting a strong second quarter driven by the robust performance of its blockbuster weight loss...
-
Roche sees positive results from weight-loss trials
16 May 2024 09:34
(Sharecast News) - Roche reported positive trial results for its experimental weight loss treatment on Thursday, sending shares in the Swiss drugs group higher.
-
Eli Lilly hikes sales guidance by $2bn, shares jump
30 April 2024 13:40
(Sharecast News) - Shares in Eli Lilly jumped on Wall Street on Tuesday after the American pharma giant beat quarterly profit forecasts and hiked its full-year sales guidance by $2bn, helped by surging...
-
Eli Lilly weight-loss drug 'significantly' reduces sleep apnoea
17 April 2024 13:15
(Sharecast News) - Eli Lily's weight-loss drug tirzepatide has been shown to "significantly" reduce sleep apnoea severity, the US drugs giant said on Wednesday.
-
Eli Lilly to buy Point Biopharma in $1.4bn deal
3 October 2023 12:35
(Sharecast News) - Eli Lilly said on Tuesday that it has agreed to buy radiopharmaceutical company Point Biopharma in a $1.4bn cash deal.
-
Eli Lilly hikes guidance despite first-quarter earnings miss
27 April 2023 11:37
(Sharecast News) - American pharmaceuticals maker Eli Lilly reported continued core business growth and pipeline momentum in its first-quarter numbers on Thursday, despite missing Wall Street expectations on...
-
Eli Lilly to buy genetic medicine developer Akouos for $487m
18 October 2022 12:16
(Sharecast News) - Eli Lilly said on Tuesday that it has agreed to buy genetic medicine developer Akouos for $487m
Company announcements Announcements
No company announcements about Eli Lilly USD (CDI) were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.